期刊文献+

COPD继发性肺动脉高压患者血清中几种生物学活性物质的变化 被引量:13

Correlation between serum marker variations and pulmonary hypertension secondary to chronic obstructive pulmonary disease
下载PDF
导出
摘要 目的明确血浆中C反应蛋白、内皮素.1、白介素.6、脑尿钠肽的水平与慢性阻塞性肺病(COPD)及COPD继发性肺动脉高压发生的相关性。方法研究对象来源于西安交通大学医学院第二附属医院呼吸内科2011年2月-2013年2月收治的174例COPD急性加重期患者。以多普勒心脏超声估测肺动脉收缩压力,并将肺动脉压力升高者分为轻度、中度及重度。采用ELISA试剂盒检测各血清学指标的水平。结果各血清学指标在单纯COPD患者组较对照组明显升高(P〈0.05),且在COPD合并肺动脉压力升高组患者均较单纯COPD患者组升高(P〈O.05)。其水平的升高与COPD继发的肺动脉压力升高程度(限于轻、中度肺动脉压力升高)呈显著正相关性,而COPD继发重度肺动脉高压时,仅脑尿钠肽的水平会随着肺动脉压力升高而增加(P〈0.05),其余指标并未进一步升高(P〉0.05)。结论早期、动态、联合监测上述血清学指标变化,可及时预警和估测COPD患者肺动脉压力的升高及其程度,对于早期诊断、治疗COPD继绽l生肺动脉高压及判断COPD预后有着重要的临床意义。 Objective To examine the correlation of the changes in the serum markers (C-reactive protein, endothelin-1, interleukin-6, and brain natriuretic peptide) with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension secondary to COPD. Methods A total of 174 COPD patients with acute exacerbation, admitted between February 2011 and February, 2013, were enrolled in this study, with 43 volunteers with normal pulmonary functions as controls. Pulmonary arterial pressure was determined by Doppler echocardiograph, and the severities (mild, moderate and severe) of PH secondary to COPD was evaluated. The levels of serum markers were determined using ELISA kits. Results The levels of serum markers in patients with COPD was significantly elevated compared with those of the control subjects (P〈0.05), and further increased in patients with pulmonary hypertension secondary to COPD (P〈0.05). A positive correlation was found between these serum markers and pulmonary artery pressure in COPD patients with mild and moderate pulmonary hypertension. In patients with severe pulmonary hypertension, only the serum level of brain natriuretic peptide continued to increase with pulmonary artery pressure (P〈0.05), and the other markers did not further increase. Conclusions Early and combined examination of these serum markers in patients with COPD can help to identify pulmonary hypertension in early stage and estimate the severity of pulmonary hypertension. Hemodynamic monitoring of the changes of these serum markers can be of important clinical value in the treatment of pulmonary hypertension secondary to COPD and in evaluation of the prognosis of COPD.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2013年第10期1458-1462,共5页 Journal of Southern Medical University
基金 国家自然科学基金(81070045) 卫生部部属(管)医院临床学科重点项目(111)~~
关键词 慢性阻塞性肺病 肺动脉高压 血清学指标 chronic obstructive pulmonary disease pulmonary hypertension serum markers
  • 相关文献

参考文献26

  • 1Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD[J]. Eur Respir J, 2008, 32(5): 1371-85.
  • 2Falk JA, Kadiev S, Gj C, et al. Cardiac disease in chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2008, 5(4): 543-8.
  • 3Wang C, Liu J, Guo F, et al. Endothelin-I induces the expression of C-reactive protein in rat vascular smooth muscle cells[J]. Biochem Biophys Res Commun, 2009, 389(3): 537-42.
  • 4Chaouat A, Savale L, Chouaid C, et al. Role for interleukin-6 in COPD-related pulmonary hypertension [J]. Chest, 2009, 136(3): 678-87.
  • 5蒋延文,庞莉,方秋红,马迎民.血清炎性因子水平与慢性阻塞性肺疾病继发肺动脉高压的相关性研究[J].中华结核和呼吸杂志,2011,34(12):904-908. 被引量:48
  • 6Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT) [J]. Eur Heart J, 2009, 30(20): 2493-537.
  • 7Zakynthinos E, Daniil Z, Papanikolaou J, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets[J]. Curt Drug Targets, 2011, 12(4): 501-13.
  • 8刘凌云,曾勉,谢灿茂,高景辉,严英硕,卢桂芳,王辉,贺云鹏.慢性阻塞性肺病患者氧化应激状态及其与糖皮质激素受体水平的相关性[J].南方医科大学学报,2008,28(6):992-996. 被引量:12
  • 9Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension[J]. J Am Coil Cardiol, 2009, 53(14): 1211-8.
  • 10Inoue Y, Kawayama T, Iwanaga T, et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale[J]. Intern Med, 2009, 48(7): 503-12.

二级参考文献35

  • 1曾勉,吴健锋,谢灿茂,严英硕,陈冬梅,禤建美.慢性阻塞性肺疾病急性加重期患者规范化痰诱导安全性的初步研究[J].中华结核和呼吸杂志,2005,28(4):238-241. 被引量:45
  • 2Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease : current theories of pathogenesis and their implications for treatment. Thorax, 2005, 60: 605-609.
  • 3Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J, 2002, 19: 632-638.
  • 4Jyothula S, Safdar Z. Update on pulmonary hypertension complicating chronic obstructive puhnonary disease. Int J Chron Obstruct Pulmon Dis, 2009, 4 : 351-363.
  • 5Peinado V, Barbera J, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1999, 159 : 1605- 1611.
  • 6Saetta M, Baraldo S, Corbino L, et al. CD8 + ve cells in the lungs of smokers with chronic obstructive pulmonary diesase. Am J Respir Crit Care Med, 1999, 160: 711-717.
  • 7Fujita M, Shannon JM, hvin CG, et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2001, 280 : L39-IA9.
  • 8Dorfmller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension Eur Respir J, 2003,22:358-363.
  • 9Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004,59:574- 580.
  • 10Pinto-Plata VM, Mtillerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax,2006, 61:23-28.

共引文献58

同被引文献98

引证文献13

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部